Get the Stockscreener App
118.67
0.73%
-1.275
Axsome Therapeutics Inc stock is traded at $118.67, with a volume of 297.71K.
It is down -0.73% in the last 24 hours and down -4.88% over the past month.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
See More
Previous Close:
$119.94
Open:
$119.81
24h Volume:
297.71K
Relative Volume:
0.52
Market Cap:
$5.92B
Revenue:
$338.46M
Net Income/Loss:
$-310.96M
P/E Ratio:
-18.17
EPS:
-6.53
Net Cash Flow:
$-132.82M
1W Performance:
-1.97%
1M Performance:
-4.88%
6M Performance:
+20.87%
1Y Performance:
+41.47%
1-Day Range:
$117.50
$120.78
1-Week Range:
$117.50
$124.53
52-Week Range:
$75.56
$139.13
Axsome Therapeutics Inc Stock (AXSM) Company Profile
Name
Axsome Therapeutics Inc
Sector
Industry
Phone
(212) 332-3241
Address
ONE WORLD TRADE CENTER, 29TH FLOOR, NEW YORK
Compare AXSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AXSM
Axsome Therapeutics Inc
|
118.67 | 5.99B | 338.46M | -310.96M | -132.82M | -6.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
411.01 | 103.30B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
583.25 | 62.05B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.04 | 59.25B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
795.95 | 48.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
342.21 | 37.84B | 4.56B | -176.77M | 225.30M | -1.7177 |
Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-01-25 | Initiated | B. Riley Securities | Buy |
| Sep-03-25 | Resumed | Wells Fargo | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Jun-03-25 | Initiated | Oppenheimer | Outperform |
| Apr-07-25 | Initiated | Jefferies | Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-31-24 | Reiterated | Mizuho | Outperform |
| Sep-03-24 | Initiated | Wells Fargo | Overweight |
| Aug-06-24 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-22-24 | Initiated | Needham | Buy |
| Apr-29-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-19-24 | Initiated | Robert W. Baird | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Jan-25-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Aug-08-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-05-23 | Initiated | Piper Sandler | Neutral |
| Nov-01-22 | Initiated | Loop Capital | Buy |
| Sep-07-22 | Resumed | Mizuho | Buy |
| Aug-10-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-10-21 | Initiated | Berenberg | Buy |
| Jan-08-21 | Initiated | Jefferies | Buy |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Sep-29-20 | Initiated | BofA Securities | Underperform |
| Sep-10-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-14-20 | Initiated | Cowen | Outperform |
| Dec-30-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-17-19 | Reiterated | H.C. Wainwright | Buy |
| Dec-16-19 | Reiterated | Guggenheim | Buy |
| Oct-16-19 | Initiated | Guggenheim | Buy |
| Sep-18-19 | Initiated | William Blair | Outperform |
| May-28-19 | Initiated | SunTrust | Buy |
| May-23-19 | Reiterated | H.C. Wainwright | Buy |
| Apr-08-19 | Initiated | SVB Leerink | Outperform |
| Mar-15-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-03-16 | Resumed | Brean Capital | Buy |
| Dec-15-15 | Initiated | Cantor Fitzgerald | Buy |
| Dec-14-15 | Initiated | Ladenburg Thalmann | Buy |
View All
Axsome Therapeutics Inc Stock (AXSM) Latest News
Axsome Therapeutics Schedule Third Quarter 2025 Financial Results Announcement and Conference Call - Quiver Quantitative
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - The Manila Times
Q3 2025 Results Nov 3: Axsome Therapeutics to Report Results and Host 8:00 AM ET Conference Call; Webcast - Stock Titan
Is Axsome Therapeutics Inc 19X a good long term investmentVolatility Adjusted Trading & Free Trading Psychology Sessions - earlytimes.in
Can Axsome Therapeutics Inc. stock withstand economic slowdownWeekly Trade Analysis & Verified Momentum Stock Alerts - newser.com
Will Axsome Therapeutics Inc. (19X) stock outperform global peersM&A Rumor & High Conviction Trade Alerts - newser.com
J. Safra Sarasin Holding AG Purchases 9,998 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Meet Herriot Tabuteau, The Haitian-Born Doctor Whose Brain Disorder Medications Turned Into A $6 Billion Empire - Black Enterprise
What is B. Riley's Estimate for AXSM Q3 Earnings? - MarketBeat
Real time social sentiment graph for Axsome Therapeutics Inc.Take Profit & Weekly Breakout Stock Alerts - newser.com
Piper Sandler Maintains Overweight on Axsome (AXSM), Sees Growth in AD-Agitation - Yahoo Finance
Migraine Market Growth to Surge During Forecast Period (2024–2034), Says DelveInsight | Eli Lilly and Company, Teva Pharmaceuticals, Axsome Therapeutics, AEON Biopharma, Inc., Charleston Laboratories - Barchart.com
Axsome Therapeutics (NASDAQ:AXSM) Upgraded by B. Riley to Strong-Buy Rating - MarketBeat
B. Riley Securities Initiates Coverage of Axsome Therapeutics (AXSM) with Buy Recommendation - Nasdaq
AXSM: New 'Buy' Rating from B. Riley Securities with $179 PT | A - GuruFocus
How Axsome Therapeutics Inc. (19X) stock trades after rate cuts2025 Support & Resistance & Intraday High Probability Setup Alerts - newser.com
B. Riley Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $179 - 富途牛牛
Will Axsome Therapeutics Inc. (19X) stock deliver stable dividendsJuly 2025 Chart Watch & Risk Controlled Daily Trade Plans - newser.com
Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN
H.C. Wainwright maintains Axsome stock Buy rating, $190 target - MSN
14 Best Biotech Stocks to Buy Right Now - Insider Monkey
Can Auvelity Drive Axsome's Growth Through the Rest of 2025? - The Globe and Mail
Obstructive Sleep Apnea Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma - Barchart.com
Obstructive Sleep Apnea Market Insights Highlight Expanding - openPR.com
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 Years - Mitrade
Axsome Sues Apotex to Block Copies of Symbravo Migraine Drug - Bloomberg Law News
Axsome Therapeutics ($AXSM) Is Paying a $7.75M Settlement to Investors — Here’s How to Get Your Shar - TradingView
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $148 - 富途牛牛
Axsome Settles Investors' Drug Approval Suit For $7.8M - Law360
Axsome Therapeutics ($AXSM) $7.75M Investor Settlement - TradingView
Axsome Therapeutics and $AXSM Investors Finalise $7.75M Settlement Agreement - TradingView
Cantor Fitzgerald Has Weak Forecast for AXSM FY2026 Earnings - MarketBeat
Assenagon Asset Management S.A. Cuts Stake in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Axsome therapeutics COO Jacobson sells $1.15 million in shares By Investing.com - Investing.com Canada
Axsome therapeutics COO Jacobson sells $1.15 million in shares - Investing.com
Axsome Therapeutics (NASDAQ:AXSM) COO Mark L. Jacobson Sells 10,000 Shares - MarketBeat
Axsome to Settle Class Suit Over Migraine Drug for $7.75 Million - Bloomberg Law News
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Buy" by Analysts - MarketBeat
Axsome Therapeutics (NASDAQ:AXSM) COO Sells $5,241,237.84 in Stock - MarketBeat
Pallas Capital Advisors LLC Purchases 2,492 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
10,400 Shares in Axsome Therapeutics, Inc. $AXSM Acquired by Strs Ohio - MarketBeat
Herriot Tabuteau Sells 15,254 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Herriot Tabuteau Sells 27,907 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Herriot Tabuteau Sells 19,719 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat
Market Moves: Can Axsome Therapeutics Inc. continue delivering strong returnsTrade Risk Assessment & Stepwise Swing Trade Plans - khodrobank.com
Intech Investment Management LLC Boosts Position in Axsome Therapeutics, Inc. $AXSM - MarketBeat
How Investors May Respond To Axsome Therapeutics (AXSM) Showcasing Late-Stage CNS Pipeline Data at Psych Congress - Yahoo Finance
Axsome Therapeutics Inc Stock (AXSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.17%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):